Usage
- This combination drug is primarily prescribed for hypertension (high blood pressure). It is used when monotherapy or dual therapy is insufficient to control blood pressure.
- Pharmacological Classification: Antihypertensive (a combination of a thiazide-like diuretic, a calcium channel blocker, and an angiotensin II receptor blocker).
- Mechanism of Action: This triple combination therapy targets different mechanisms involved in blood pressure regulation. Chlorthalidone reduces blood volume by increasing sodium and water excretion. Cilnidipine relaxes and widens blood vessels by blocking calcium channels. Irbesartan blocks the action of angiotensin II, a hormone that narrows blood vessels.
Alternate Names
- Irbesartan/Chlorthalidone/Cilnidipine
- Clindasartan-CH
How It Works
- Pharmacodynamics: Chlorthalidone increases urinary excretion of sodium and water, reducing blood volume and lowering blood pressure. Cilnidipine inhibits calcium influx into vascular smooth muscle, causing vasodilation. Irbesartan blocks angiotensin II receptors, preventing vasoconstriction and reducing aldosterone secretion.
- Pharmacokinetics:
- Absorption: All three drugs are orally absorbed.
- Metabolism: Irbesartan is partially metabolized by the liver. Cilnidipine is extensively metabolized by the liver, primarily by CYP3A4. Chlorthalidone is not extensively metabolized.
- Elimination: Irbesartan is eliminated via both biliary/fecal and renal routes. Cilnidipine and its metabolites are primarily eliminated in the feces, with a small portion eliminated in urine. Chlorthalidone is primarily excreted unchanged in the urine.
- Mode of Action: Chlorthalidone acts on the distal convoluted tubule in the kidneys. Cilnidipine blocks L-type calcium channels in vascular smooth muscle. Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors.
Dosage
Standard Dosage
Adults:
- Initial dose: Irbesartan 150 mg/Chlorthalidone 6.25 mg/Cilnidipine 10 mg once daily, usually in the morning with food.
- Maximum dose: Irbesartan 300 mg/Chlorthalidone 12.5 mg/Cilnidipine 20 mg once daily. Dosage titration should be based on individual patient response.
Children:
- Safety and efficacy not established in children.
Special Cases:
- Elderly Patients: Start with a lower dose of Irbesartan (e.g., 75 mg) and titrate cautiously.
- Patients with Renal Impairment: Dose adjustment is needed, especially with severe impairment. May be contraindicated in severe cases.
- Patients with Hepatic Dysfunction: Use with caution and monitor for adverse effects. Dose adjustment may be necessary.
- Patients with Comorbid Conditions: Close monitoring of patients with diabetes, gout, heart failure, or electrolyte imbalances is necessary.
Side Effects
Common Side Effects:
- Dizziness, headache, fatigue
- Swelling (peripheral edema), flushing
- Nausea
Rare but Serious Side Effects:
- Hypotension, electrolyte imbalances (hypokalemia, hyponatremia)
- Renal dysfunction, hepatic dysfunction
- Angioedema (rare but serious allergic reaction)
Contraindications
- Hypersensitivity to any component of the drug
- Severe renal or hepatic impairment
- Anuria
- Pregnancy
- Concurrent use of aliskiren in patients with diabetes
Drug Interactions
- Other antihypertensives (additive hypotensive effects)
- NSAIDs (may reduce antihypertensive effect)
- Potassium supplements or potassium-sparing diuretics (risk of hyperkalemia)
- Lithium (increased lithium levels)
- Digoxin (increased digoxin levels)
- Grapefruit juice (may increase Cilnidipine levels)
- Alcohol (may increase the risk of hypotension)
Pregnancy and Breastfeeding
- Pregnancy: Contraindicated. Can cause fetal harm, especially in the second and third trimesters.
- Breastfeeding: Not recommended. Consult a physician for safer alternatives.
Drug Profile Summary
- Mechanism of Action: Irbesartan (ARB), Chlorthalidone (diuretic), Cilnidipine (CCB)
- Side Effects: Dizziness, headache, fatigue, swelling, flushing, nausea. Serious: Hypotension, electrolyte imbalances, renal/hepatic dysfunction, angioedema.
- Contraindications: Hypersensitivity, severe renal/hepatic impairment, anuria, pregnancy, concurrent aliskiren use in diabetic patients.
- Drug Interactions: Other antihypertensives, NSAIDs, potassium supplements, lithium, digoxin, grapefruit juice.
- Pregnancy & Breastfeeding: Contraindicated in pregnancy; Caution during breastfeeding.
- Dosage: Initial: Irbesartan 150/Chlorthalidone 6.25/Cilnidipine 10 mg once daily; titrate to max 300/12.5/20 mg. Adjustments needed for renal/hepatic impairment, elderly patients.
- Monitoring Parameters: Blood pressure, renal function (serum creatinine, BUN), electrolytes (potassium, sodium, chloride, uric acid), liver enzymes, blood glucose, lipid profile.
Popular Combinations
While this drug itself combines three agents, additional antihypertensives may be necessary if blood pressure remains uncontrolled. The choice of additional agent depends on patient-specific factors.
Precautions
- Pre-screening for underlying medical conditions (renal/hepatic function, electrolyte levels) is essential.
- Monitor for side effects and drug interactions.
- Advise patients on lifestyle modifications (diet, exercise, sodium restriction) and medication adherence.
FAQs (Frequently Asked Questions)
Q1: What is the recommended dosage for Chlorthalidone + Cilnidipine + Irbesartan?
A: The initial dose is Irbesartan 150 mg/Chlorthalidone 6.25 mg/Cilnidipine 10 mg once daily. The maximum dose is 300/12.5/20 mg once daily. Dose adjustments are necessary for elderly patients and those with renal or hepatic impairment.
Q2: What are the common side effects?
A: Dizziness, headache, fatigue, swelling, flushing, and nausea are common side effects.
Q3: Is this combination safe during pregnancy?
A: No, it is contraindicated during pregnancy due to potential harm to the fetus.
Q4: What if a dose is missed?
A: Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double the dose to catch up.
Q5: Can this combination be used with other antihypertensives?
A: It can, but with careful monitoring for additive hypotensive effects. The decision to combine it with other antihypertensives depends on individual patient response and blood pressure control.
Q6: Does this medication interact with grapefruit juice?
A: Yes, grapefruit juice can increase Cilnidipine levels. Patients should avoid grapefruit juice while taking this combination.
Q7: What should patients with renal impairment do?
A: Patients with renal impairment should inform their doctor as dose adjustments are needed. It may even be contraindicated in severe renal impairment.
Q8: Are there any specific monitoring parameters for this drug?
A: Yes, monitor blood pressure, renal function, electrolytes (especially potassium and sodium), liver enzymes, blood glucose, and lipid profile.
Q9: What is the mechanism of action of each component?
A: Chlorthalidone is a thiazide-like diuretic, Cilnidipine is a calcium channel blocker, and Irbesartan is an angiotensin II receptor blocker. They act synergistically to lower blood pressure via different pathways.